Highest-materiality recent filing
Alaunos reports ALN1003 preclinical data: -12.9% weight loss, liver weight -43%; cash only $0.35M
ALN1003 in DIO mice: mean body weight change -12.9% by Day 33 and -10.3% by Day 48 (p<0.0001).
Alaunos announces preclinical ALN1003 data; cash only $0.354M, runway into Q2 2026
ALN1003 showed significantly lower HOMA-IR (p=0.0006) and higher adiponectin-to-leptin ratio in DIO mouse models.
Alaunos Therapeutics receives Nasdaq delisting notice for equity shortfall; 45 days to submit plan
Nasdaq notified Alaunos on April 9, 2026, of non-compliance with minimum $2.5M stockholders' equity; 2025 10-K reported $2.153M.
Alaunos reports positive preclinical data for ALN1003; weight loss up to 12.9% in DIO mice
ALN1003 showed dose-dependent body weight loss: -12.9% peak (Day 34) and -10.3% after 48 days vs DIO control (p<0.0001).
Alaunos reports positive preclinical obesity data but cash runway only through Q1 2026
Preclinical DIO mouse study shows statistically significant dose-related weight loss and improved body composition; lead compound identified.
Alaunos regains Nasdaq compliance after reporting $3.66M equity in Q2 2025
Nasdaq notified Alaunos of compliance on August 19, 2025, following prior stockholders' equity deficiency.
Alaunos shareholders approve 10x increase in authorized common shares, reverse split authorization
Stockholders approved increasing authorized common shares from 5M to 50M; amendment effective July 10, 2025.
Dale Curtis Hogue Jr. resigned as CEO and director effective July 1, 2025; no disagreement.
Alaunos Therapeutics raises $850K via private placement of Series A-2 Convertible Preferred Stock
Aggregate purchase price of $850,000 from accredited investors; offering closed June 24, 2025.
Alaunos Therapeutics raises ~$2.05M in registered direct offering of stock and pre-funded warrants
338,725 shares at $3.36; 271,674 pre-funded warrants at $3.359/share.
Alaunos Therapeutics enters $25M equity purchase agreement with Mast Hill Fund
Mast Hill commits to buy up to $25M of common stock over 24 months at Company's discretion.
Alaunos receives Nasdaq deficiency notice for equity below $2.5M minimum; 45 days to submit plan
Stockholders' equity of $2.063M as of Dec 31, 2024, falls short of Nasdaq's $2.5M minimum under Rule 5550(b)(1).
Terminated Amended and Restated License Agreement with Precigen effective Oct 4, 2024; Sleeping Beauty patent expiry in 2026 cited.
Alaunos Therapeutics to effect 1-for-10 reverse stock split on July 17, 2024
Board approved 1-for-10 reverse split; authorized by shareholders on June 6, 2024.
Alaunos shareholders approve reverse stock split (1:5-1:15) and authorized share increase to 50M
Stockholders approved reverse stock split at ratio between 1-for-5 and 1-for-15, at Board's discretion, effective June 12, 2024.
Robert Hofmeister, Ph.D. Resignation On April 15, 2025, Dr. Hofmeister resigned as a member of the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) with immediate effect.
On February 15, 2024, Michael Wong gave notice of his resignation as Vice President, Finance, of Alaunos Therapeutics, Inc. (the "Company"), effective February 23, 2024.
On February 22, 2024, the Company and Ferdinand Groenewald entered into a consulting agreement (the “Consulting Agreement”), effective February 22, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company’s Vice President, Finance.
Max materiality 0.80 · Median 0.60 · Most common event other_material